BofA raised the firm’s price target on Tempus AI (TEM) to $60 from $54 and keeps a Neutral rating on the shares after the company reported Q4 ...

Skyrocketing 108% since the start of 2025, Tempus AI (NASDAQ: TEM), a company applying AI solutions to healthcare, has seen ...

DeepSeek is a stark reminder about the importance of strategic durability, and not just growth or growth potential, to a ...

A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...

Cathie Wood and Ark Invest seized the opportunity on Tuesday to buy the dip on Tempus AI (NASDAQ:TEM) as the stock took a 15% ...

Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics, a well-known leader in ...

Key Takeaways Tempus AI's fourth-quarter results missed estimates as its costs increased.The medical technology firm's ...

Tempus AI's slowing growth, cash flow issues, and net debt raise doubts about its sustainability. Explore key concerns and ...

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results. See why I remain bullish on ...

Despite optimistic news from the CEO yesterday afternoon, the company's shares fell overnight and a major investment house ...

Tempus announced its acquisition of Ambry Genetics at closing in November and the deal closed earlier this month.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...